Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 4:42 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 358 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Overactive Bladder Clear all
Completed Not applicable Interventional Results available

Safety and Effectiveness of a Non-invasive Neuromodulation Device on Urgency Urinary Incontinence in Overactive Bladder

NCT01369485
View directory record Official record
Conditions
Overactive Bladder
Interventions
(VERV™ System), Sham version of (VERV™ System)
Device
Lead sponsor
Ethicon Endo-Surgery
Industry
Eligibility
18 Years and older
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
14
States / cities
Tucson, Arizona • Murrieta, California • Washington D.C., District of Columbia + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2014 · Synced Jul 21, 2026, 4:42 PM EDT
Completed Not applicable Interventional

Ease of Use Study of the FemPulse System

NCT06885099
View directory record Official record
Conditions
Overactive Bladder (OAB)
Interventions
FemPulse System
Device
Lead sponsor
FemPulse Corporation
Industry
Eligibility
21 Years and older · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Fort Lauderdale, Florida
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Jul 21, 2026, 4:42 PM EDT
Completed Phase 4 Interventional Results available

Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects With Overactive Bladder (OAB)

NCT02216214
View directory record Official record
Conditions
Overactive Bladder (OAB)
Interventions
Mirabegron, Placebo
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
65 Years and older
Enrollment
888 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
103
States / cities
Huntsville, Alabama • Mobile, Alabama • Anchorage, Alaska + 88 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2024 · Synced Jul 21, 2026, 4:42 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Long-term Follow-up Study of Patients Who Received EG110A, a Non-replicative Herpes Simplex Virus 1-derived Gene Therapy

NCT07227285
View directory record Official record
Conditions
Urinary Bladder, Overactive, Spinal Cord Injury
Interventions
Urodynamics, EG110A, Patient-reported Outcome
Other · Drug
Lead sponsor
Cyllene Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
4
States / cities
Downey, California • Ann Arbor, Michigan • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 11, 2025 · Synced Jul 21, 2026, 4:42 PM EDT
Terminated Phase 3 Interventional Results available

OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Overactive Bladder in Pediatric Patients (12 to 17)

NCT02097121
View directory record Official record
Conditions
Urinary Incontinence, Urinary Bladder, Overactive
Interventions
BOTOX®
Biological
Lead sponsor
Allergan
Industry
Eligibility
12 Years to 17 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
8
States / cities
Anchorage, Alaska • Little Rock, Arkansas • Aurora, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2022 · Synced Jul 21, 2026, 4:42 PM EDT
Not listed Not applicable Interventional

Electrical Nerve Stimulation for Overactive Bladder a Comparison of Treatments

NCT01940367
View directory record Official record
Conditions
Overactive Bladder, Urge Urinary Incontinence
Interventions
PTNS (Percutaneous Tibial Nerve Stimulation, TENS (Transcutaneous Electrical Nerve Stimulation)
Device
Lead sponsor
Walter Reed National Military Medical Center
Federal
Eligibility
18 Years and older · Female only
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
3
States / cities
Bethesda, Maryland • Fort Belvoir, Virginia • Portsmouth, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 27, 2016 · Synced Jul 21, 2026, 4:42 PM EDT
Completed Phase 3 Interventional Results available

A Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder

NCT00912964
View directory record Official record
Conditions
Urinary Bladder, Overactive
Interventions
Mirabegron, Placebo
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
2,030 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
82
States / cities
Homewood, Alabama • Huntsville, Alabama • Mobile, Alabama + 75 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2024 · Synced Jul 21, 2026, 4:42 PM EDT
Withdrawn Phase 2 Interventional

Botulinum-A Toxin Injection for Detrusor Hyperreflexia in Spinal Cord Injury: A Non-Surgical Approach.

NCT00262496
View directory record Official record
Conditions
Overactive Bladder, Urinary Incontinence
Interventions
Botox
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 25, 2015 · Synced Jul 21, 2026, 4:42 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Comparative Urine Proteomic Studies of Overactive Bladder in Humans

NCT01367886
View directory record Official record
Conditions
Overactive Bladder
Interventions
fesoterodine
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 26, 2015 · Synced Jul 21, 2026, 4:42 PM EDT
Withdrawn Not applicable Interventional

Neuromodulation Implantation Settings Variation for Overactive Bladder

NCT02112786
View directory record Official record
Conditions
Overactive Bladder
Interventions
Intermittent or Continuous Setting RestorePrime Implanted Impulse Generator
Device
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Jan 25, 2015 · Synced Jul 21, 2026, 4:42 PM EDT
Active, not recruiting Not applicable Interventional

Trial for Reliability of Urodynamics SysTem

NCT05694793
View directory record Official record
Conditions
Urologic Diseases, Urodynamics
Interventions
Glean Urodynamics System
Device
Lead sponsor
Bright Uro
Industry
Eligibility
18 Years and older · Female only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
3
States / cities
Murrieta, California • San Diego, California • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Jul 21, 2026, 4:42 PM EDT
Completed Phase 3 Interventional Results available

A Clinical Trial To Assess Fesoterodine On Treatment Satisfaction And Symptom Improvement In Overactive Bladder Patients

NCT00425100
View directory record Official record
Conditions
Overactive Bladder
Interventions
fesoterodine fumarate
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
516 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
24
States / cities
Homewood, Alabama • Huntsville, Alabama • La Mesa, California + 20 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2018 · Synced Jul 21, 2026, 4:42 PM EDT
Terminated Not applicable Interventional

INvestigation of TENS Efficacy Versus Posterior Tibial Nerve Stimulation for Overactive Bladder

NCT05309993
View directory record Official record
Conditions
Overactive Bladder, Overactive Bladder Syndrome, Urinary Urge Incontinence, Urinary Bladder, Overactive, Urinary Incontinence, Urge
Interventions
PTNS, TENS
Device
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years and older · Female only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Oct 30, 2025 · Synced Jul 21, 2026, 4:42 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

The Effect of Anticholinergics on Cognitive Function in the Elderly

NCT01922115
View directory record Official record
Conditions
Mental Competency, Urinary Bladder, Overactive, Cognitive Function
Interventions
Trospium Chloride, Placebo
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
50 Years to 99 Years · Female only
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 21, 2017 · Synced Jul 21, 2026, 4:42 PM EDT
Completed Phase 3 Interventional Results available

Anticholinergic vs. Botox Comparison Study

NCT01166438
View directory record Official record
Conditions
Urge Urinary Incontinence, Overactive Bladder
Interventions
Botulinum toxin A (Botox A®), Solifenacin 5mg, Solifenacin 10mg, Trospium chloride
Drug
Lead sponsor
NICHD Pelvic Floor Disorders Network
Network
Eligibility
21 Years and older · Female only
Enrollment
249 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
11
States / cities
Birmingham, Alabama • La Jolla, California • San Diego, California + 8 more
Source: ClinicalTrials.gov public record
Updated May 1, 2018 · Synced Jul 21, 2026, 4:42 PM EDT
Completed Phase 2 Interventional

Urinary Microbiome Changes Following Administration of 500 mg of NDS-446 in Women With Dry OAB at 12 Weeks

NCT05557279
View directory record Official record
Conditions
Overactive Bladder
Interventions
500 mg NDS-446
Drug
Lead sponsor
Loyola University
Other
Eligibility
18 Years to 99 Years · Female only
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Jul 21, 2026, 4:42 PM EDT
Completed Phase 3 Interventional

A Long-Term Safety, Tolerability and Efficacy Study of Darifenacin in Adult Patients With Overactive Bladder

NCT00170755
View directory record Official record
Conditions
Overactive Bladder Syndrome
Interventions
Darifenacin
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
718 participants
Timeline
2002 – 2005
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 16, 2008 · Synced Jul 21, 2026, 4:42 PM EDT
Completed Phase 4 Interventional Results available

Study of 2 Doses of Solifenacin Succinate in Female Subjects With Overactive Bladder.

NCT01093534
View directory record Official record
Conditions
Detrusor Overactivity, Overactive Bladder
Interventions
Placebo, solifenacin
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older · Female only
Enrollment
547 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
3
States / cities
New York, New York • West Reading, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 2, 2024 · Synced Jul 21, 2026, 4:42 PM EDT
Not listed Early Phase 1 Interventional

Repetitive Transcranial Magnetic Stimulation in Women With Overactive Bladder With Urgency Incontinence

NCT05099419
View directory record Official record
Conditions
Overactive Bladder, Urge Incontinence
Interventions
Repetitive Transcranial Magnetic Stimulation
Device
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 16, 2021 · Synced Jul 21, 2026, 4:42 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Pilot Study to Assess Effects of Self-Administered Nitrous Oxide (SANO) on Urodynamic Study (UDS) Parameters

NCT05883332
View directory record Official record
Conditions
Lower Urinary Tract Symptoms
Interventions
Self-Administered Nitrous Oxide, Oxygen
Drug · Other
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
21 Years to 85 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Jul 21, 2026, 4:42 PM EDT
Active, not recruiting Not applicable Interventional

INTIBIA Pivotal Study

NCT05250908
View directory record Official record
Conditions
Urinary Incontinence, Urge, Urinary Bladder, Overactive, Urinary Bladder Diseases, Urologic Diseases, Lower Urinary Tract Symptoms, Urological Manifestations
Interventions
INTIBIA Therapeutic, INTIBIA Non-Therapeutic
Device
Lead sponsor
Coloplast A/S
Industry
Eligibility
22 Years to 80 Years
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
20
States / cities
Beverly Hills, California • Los Angeles, California • Washington D.C., District of Columbia + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2026 · Synced Jul 21, 2026, 4:42 PM EDT
Completed Phase 4 Interventional Results available

Minimizing Pain During Office Intradetrussor Botox Injection

NCT04270526
View directory record Official record
Conditions
Overactive Bladder, Overactive Detrusor, Overactive Bladder Syndrome, Overactivity; Behavior, Urge Incontinence
Interventions
Bicarbonate protocol, Standard protocol
Drug
Lead sponsor
Boston Urogynecology Associates
Other
Eligibility
18 Years and older · Female only
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 5, 2025 · Synced Jul 21, 2026, 4:42 PM EDT
Recruiting Not applicable Interventional

Ambulatory Long Length URodynamics Evaluation

NCT07425015
View directory record Official record
Conditions
Urology, Urinary Bladder, Overactive, Benign Prostatic Hyperplasia, Urodynamics, Home Monitoring, Urinary Incontinence (UI), Lower Urinary Tract Dysfunction
Interventions
Glean Urodynamics System
Device
Lead sponsor
Bright Uro
Industry
Eligibility
22 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
7
States / cities
Hanover, Maryland • Owings Mills, Maryland • St Louis, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Jul 21, 2026, 4:42 PM EDT
Not yet recruiting Phase 4 Interventional

Optimal Intravesical Lidocaine Volume for Pain Relief During Office Intra-detrusor Onabotulinum Toxin a Injections

NCT06695585
View directory record Official record
Conditions
Overactive Bladder, Overactive Bladder Syndrome, Urinary Urgency, Urinary Frequency, Urge Incontinence, Neurogenic Bladder
Interventions
Lidocaine 2% without vessel constrictor
Drug
Lead sponsor
University of Louisville
Other
Eligibility
18 Years and older · Female only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Nov 18, 2024 · Synced Jul 21, 2026, 4:42 PM EDT